Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.

ClinicalTrials.gov ID: NCT02970669

Public ClinicalTrials.gov record NCT02970669. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Ejection Fraction (AWAKE-HF).

Study identification

NCT ID
NCT02970669
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
140 participants

Conditions and interventions

Interventions

  • sacubitril/valsartan (LCZ696) Drug
  • enalapril Drug
  • matching placebo sacubitril/valsartan (LCZ696) Drug
  • matching placebo enalapril Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 15, 2016
Primary completion
Mar 18, 2018
Completion
Mar 18, 2018
Last update posted
Oct 6, 2021

2016 – 2018

United States locations

U.S. sites
23
U.S. states
9
U.S. cities
23
Facility City State ZIP Site status
Novartis Investigative Site Fort Payne Alabama 35967
Novartis Investigative Site Beverly Hills California 90211
Novartis Investigative Site Stockton California 95204
Novartis Investigative Site West Hills California 91307
Novartis Investigative Site Doral Florida 33126
Novartis Investigative Site Inverness Florida 34452
Novartis Investigative Site Ormond Beach Florida 32174
Novartis Investigative Site Port Orange Florida 32127
Novartis Investigative Site Lutherville Maryland 21093
Novartis Investigative Site East Brunswick New Jersey 08816
Novartis Investigative Site Ridgewood New Jersey 07450
Novartis Investigative Site Columbia South Carolina 29203
Novartis Investigative Site Greenville South Carolina 29615
Novartis Investigative Site Lancaster South Carolina 29720
Novartis Investigative Site Allen Texas 75002-3688
Novartis Investigative Site McKinney Texas 75013
Novartis Investigative Site New Braunfels Texas 78130
Novartis Investigative Site San Antonio Texas 78229
Novartis Investigative Site San Marcos Texas 78666
Novartis Investigative Site Sherman Texas 75092
Novartis Investigative Site Tomball Texas 77375
Novartis Investigative Site Midlothian Virginia 23114
Novartis Investigative Site Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02970669, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 6, 2021 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02970669 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →